Drugs / BT7480
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05163041 | Nov 2021 → Aug 2026 overdue | neoplasm | BicycleTx Limited | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07681674 | Aug 2026 → May 2030 expected | cancer | BicycleTx Limited | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | BicycleTx Limited | Results Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 bicycletherapeutics.com ↗
BT7480 demonstrated a favorable safety profile and preliminary antitumor activity in advanced Nectin-4-associated solid tumors |
| 2021-11-09 | BicycleTx Limited | Results Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting bicycletherapeutics.com ↗
Preclinical results that will be presented at SITC support Bicycle’s decision to initiate a Phase I/II clinical trial of BT7480 and its prioritization of potential indications to target. |
| 2021-11-02 | BicycleTx Limited | Results Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer bicycletherapeutics.com ↗
The data published today in JITC describe BT7480’s ability to elicit rapid reprogramming of the tumor immune microenvironment, which leads to complete regressions and anti-tumor immunity with only intermittent drug exposure in syngeneic mouse tumor models. |
| 2020-11-09 | BicycleTx Limited | Results Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting bicycletherapeutics.com ↗
New data presented at SITC demonstrate that treatment with BT7480 leads to significant modulation of the tumor microenvironment, including immune checkpoints. |
| 2019-11-05 | BicycleTx Limited | Results Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting bicycletherapeutics.com ↗
In preclinical experiments with BT7480, we have shown these characteristics promote rapid tumor penetration and powerful anti-tumor activity. |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT7480 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681674 ↗ |
| Action | Activate | “tumor targeted immune cell agonist” NCT05163041 ↗ |
| Modality | Peptide | “three bicyclic peptides” NCT05163041 ↗ |
| Route | Intravenous | “60 minute IV infusion of BT7480” NCT05163041 ↗ |